Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Phase Distribution

Ph not_applicable

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution1 total trials

N/ANon-phased studies

1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Other(2)

Detailed Status

Completed2

unknown2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

completed250%

unknown250%

Recent Activity

0 active trials

Showing 4 of 4

completednot_applicable

Free Time For Wellness Pilot Effectiveness Trial

NCT06474715

unknown

The Impact of Frailty in Type 2 Diabetes

NCT05863611

unknown

The Prevelence of IVS 1-6 (T-C) [HBB:c.92 +6 T-C] Gene Mutation in Suspected Cases of β Thalassemia in Assiut University Hospitals

NCT05370677

completed

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

NCT02623257

Clinical Trials (4)

Showing 4 of 4 trials

NCT06474715Not Applicable

Free Time For Wellness Pilot Effectiveness Trial

Completed

NCT05863611

The Impact of Frailty in Type 2 Diabetes

Unknown

NCT05370677

The Prevelence of IVS 1-6 (T-C) [HBB:c.92 +6 T-C] Gene Mutation in Suspected Cases of β Thalassemia in Assiut University Hospitals

Unknown

NCT02623257

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Completed

All 4 trials loaded

Drug Details

Intervention Type: BEHAVIORAL
Total Trials: 4